Published in J Virol on July 01, 2005
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol (2006) 4.74
Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol (2009) 4.20
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. J Virol (2006) 3.03
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J Virol (2007) 2.80
Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol (2007) 2.62
Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A (2007) 2.33
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem (2007) 2.07
Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol (2007) 2.05
Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol (2010) 1.98
The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J Virol (2011) 1.82
Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol (2010) 1.81
A naturally occurring deletion in its NS gene contributes to the attenuation of an H5N1 swine influenza virus in chickens. J Virol (2007) 1.80
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Dynamics of influenza virus infection and pathology. J Virol (2010) 1.62
MicroRNA-mediated species-specific attenuation of influenza A virus. Nat Biotechnol (2009) 1.61
Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2009) 1.61
Making better influenza virus vaccines? Emerg Infect Dis (2006) 1.59
Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol (2009) 1.50
Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J Virol (2006) 1.48
Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog (2012) 1.43
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun (2013) 1.37
A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF. J Virol (2008) 1.37
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 1.27
Rewiring the RNAs of influenza virus to prevent reassortment. Proc Natl Acad Sci U S A (2009) 1.25
Viral reassortment and transmission after co-infection of pigs with classical H1N1 and triple-reassortant H3N2 swine influenza viruses. J Gen Virol (2010) 1.23
Nrf2 expression modifies influenza A entry and replication in nasal epithelial cells. Free Radic Biol Med (2011) 1.21
The NS segment of an H5N1 highly pathogenic avian influenza virus (HPAIV) is sufficient to alter replication efficiency, cell tropism, and host range of an H7N1 HPAIV. J Virol (2009) 1.20
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18
Adaptive mutations resulting in enhanced polymerase activity contribute to high virulence of influenza A virus in mice. J Virol (2009) 1.18
Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol (2007) 1.17
Generation of recombinant influenza virus from plasmid DNA. J Vis Exp (2010) 1.15
Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem (2012) 1.13
Exposure to ozone modulates human airway protease/antiprotease balance contributing to increased influenza A infection. PLoS One (2012) 1.13
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe (2013) 1.13
Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles. J Virol (2009) 1.13
The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells. J Virol (2007) 1.13
Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J Virol (2010) 1.13
Antiviral response in pandemic influenza viruses. Emerg Infect Dis (2006) 1.12
The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging. J Virol (2012) 1.12
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 1.12
NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine (2010) 1.08
A nine-segment influenza a virus carrying subtype H1 and H3 hemagglutinins. J Virol (2010) 1.07
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine (2009) 1.05
Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine (2008) 1.04
Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene. J Gen Virol (2009) 1.04
Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol (2014) 1.02
Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Vet J (2009) 1.02
Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J Virol (2009) 1.01
Asparagine substitution at PB2 residue 701 enhances the replication, pathogenicity, and transmission of the 2009 pandemic H1N1 influenza A virus. PLoS One (2013) 1.01
Innate immune evasion strategies of influenza viruses. Future Microbiol (2010) 1.00
Equine influenza - surveillance and control. Influenza Other Respir Viruses (2010) 0.99
Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med (2013) 0.99
Characterization of uncultivable bat influenza virus using a replicative synthetic virus. PLoS Pathog (2014) 0.98
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog (2012) 0.96
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol (2012) 0.95
The Influenza NS1 Protein: What Do We Know in Equine Influenza Virus Pathogenesis? Pathogens (2016) 0.95
The NS1 protein of influenza A virus suppresses interferon-regulated activation of antigen-presentation and immune-proteasome pathways. J Gen Virol (2011) 0.92
Phylogenetic analysis of the non-structural (NS) gene of influenza A viruses isolated from mallards in Northern Europe in 2005. Virol J (2008) 0.91
Mutations to PB2 and NP proteins of an avian influenza virus combine to confer efficient growth in primary human respiratory cells. J Virol (2014) 0.90
Highly pathogenic avian influenza viruses do not inhibit interferon synthesis in infected chickens but can override the interferon-induced antiviral state. J Virol (2011) 0.90
Replication-competent influenza A viruses expressing a red fluorescent protein. Virology (2014) 0.89
The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA. J Virol (2014) 0.89
Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol (2006) 0.88
Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol (2014) 0.87
Attenuated influenza virus construct with enhanced hemagglutinin protein expression. J Virol (2012) 0.86
Duck MDA5 functions in innate immunity against H5N1 highly pathogenic avian influenza virus infections. Vet Res (2014) 0.86
A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) (2014) 0.85
Insertion of a GFP reporter gene in influenza virus. Curr Protoc Microbiol (2013) 0.85
Arenavirus reverse genetics for vaccine development. J Gen Virol (2013) 0.83
Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine (2008) 0.83
Induction and suppression of antiviral RNA interference by influenza A virus in mammalian cells. Nat Microbiol (2016) 0.81
Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection. Int J Parasitol (2010) 0.79
Residue 41 of the Eurasian avian-like swine influenza a virus matrix protein modulates virion filament length and efficiency of contact transmission. J Virol (2014) 0.79
Replication-Competent Influenza A and B Viruses Expressing a Fluorescent Dynamic Timer Protein for In Vitro and In Vivo Studies. PLoS One (2016) 0.78
PB2 segment promotes high-pathogenicity of H5N1 avian influenza viruses in mice. Front Microbiol (2015) 0.78
Filament-producing mutants of influenza A/Puerto Rico/8/1934 (H1N1) virus have higher neuraminidase activities than the spherical wild-type. PLoS One (2014) 0.78
Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype. J Virol (2014) 0.78
Principles underlying rational design of live attenuated influenza vaccines. Clin Exp Vaccine Res (2012) 0.78
Role of N Terminus-Truncated NS1 Proteins of Influenza A Virus in Inhibiting IRF3 Activation. J Virol (2016) 0.78
The NS segment of H5N1 avian influenza viruses (AIV) enhances the virulence of an H7N1 AIV in chickens. Vet Res (2014) 0.78
Genomic analysis and mRNA expression of equine type I interferon genes. J Interferon Cytokine Res (2013) 0.78
In vivo assessment of NS1-truncated influenza virus with a novel SLSYSINWRH motif as a self-adjuvanting live attenuated vaccine. PLoS One (2015) 0.77
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Multiple alignment comparison of the non-structural genes of three strains of equine influenza viruses (H3N8) isolated in Morocco. BMC Res Notes (2015) 0.75
A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine. J Virol (2016) 0.75
Reverse Genetics Approaches for the Development of Influenza Vaccines. Int J Mol Sci (2016) 0.75
Efficacy of Live-Attenuated H9N2 Influenza Vaccine Candidates Containing NS1 Truncations against H9N2 Avian Influenza Viruses. Front Microbiol (2017) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A (1999) 14.90
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Rescue of influenza A virus from recombinant DNA. J Virol (1999) 11.54
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol Cell (1998) 5.60
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity (2001) 5.04
A plasmid-based reverse genetics system for influenza A virus. J Virol (1996) 4.33
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95
The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). J Virol (1994) 3.48
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
A NEW INFLUENZA VIRUS ASSOCIATED WITH EQUINE RESPIRATORY DISEASE. J Am Vet Med Assoc (1963) 3.37
Isolation of a virus causing respiratory disease in horses. Acta Virol (1958) 2.81
The influenza virus NS1 protein: a novel inhibitor of pre-mRNA splicing. Genes Dev (1994) 2.64
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. Mol Cell Biol (2000) 2.48
Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol (1998) 2.42
Retracted The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res (2004) 2.15
Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis (2003) 2.05
Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis (1999) 2.02
Are equine 1 influenza viruses still present in horses? Equine Vet J (1993) 1.92
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol (2000) 1.65
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 1.63
Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. J Am Vet Med Assoc (1999) 1.49
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. J Infect Dis (1970) 1.42
Development of the interferon system. I. In chicken cells development in ovo continues on time in vitro. In Vitro Cell Dev Biol (1990) 1.39
Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol (1990) 1.31
Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis (1995) 1.14
Interferon induction by viruses. XIV. Development of interferon inducibility and its inhibition in chick embryo cells "aged" in vitro. J Interferon Res (1985) 1.07
Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J (2001) 1.05
Monitoring and detection of acute viral respiratory tract disease in horses. J Am Vet Med Assoc (1998) 0.99
Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination. Vaccine (1998) 0.98
Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression. J Am Vet Med Assoc (2001) 0.93
Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. Vaccine (2003) 0.89
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog (2007) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog (2009) 6.09
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Human host factors required for influenza virus replication. Nature (2010) 5.28
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 4.99
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol (2006) 4.74
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A (2007) 3.98
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
High temperature (30 degrees C) blocks aerosol but not contact transmission of influenza virus. J Virol (2008) 3.77
Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science (2012) 3.74
Gain-of-function experiments on H7N9. Science (2013) 3.67
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science (2007) 3.16
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol (2007) 3.04
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol (2006) 2.78
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol (2007) 2.62
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
The biology of influenza viruses. Vaccine (2008) 2.58
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 2.42
Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A (2007) 2.33
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Identification of cellular interaction partners of the influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based approaches. J Proteome Res (2007) 2.21
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol (2010) 2.17
Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol (2010) 2.17
The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J Virol (2002) 2.14
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis (2009) 2.12